Pine Pharmaceuticals
Pine Pharmaceuticals (United States) has no DMF, CEP or site registration linked in our records. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Pine Pharmaceuticals: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/pine-pharmaceuticals
Overview
Pine Pharmaceuticals is a pharmaceutical company headquartered in Tonawanda, United States.
FDA compliance signals
50 FDA enforcement records linked to this company.
- warning_letter2026-08-07
FDA Warning Letter (drug product)
- 4832024-09-30
Environmental Monitoring System
- 4832024-09-30
Written in-process control procedures
- 4832024-09-30
Absence of Written Procedures
- 4832024-09-30
Actual vs. theoretical yields not determined
- 4832024-09-30
Mfg / Processing Operations Area
- 4832024-09-30
Air Supply
- 4832024-09-30
Procedures for sterile drug products
- 4832024-09-30
Cleaning System
- 4832024-09-30
Investigations of discrepancies, failures
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- recall — Class II2023-10-25
Lack of Assurance of Sterility
- 4832023-09-19
Procedures for sterile drug products
- 4832023-09-19
Investigations of discrepancies, failures
- 4832023-09-19
Outsourcing facility, compounded drug report follow up
- 4832023-09-19
Production areas, difficult to clean/particle generating
- 4832023-09-19
Inadequate smoke studies
- 4832023-09-19
Approve or reject components, products
- 4832023-09-19
Personnel, blocked or disrupted first air
- recall — Class III2023-04-19
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
- recall — Class II2023-01-11
CGMP Deviations: Raw material recalled by repackager, due to discoloration.
- recall — Class II2022-09-21
Lack of Assurance of Sterility
- 4832021-05-14
Written calibration / inspection records not kept
- 4832021-05-14
Procedures for sterile drug products
- 4832021-05-14
Approve or reject procedures or specs
- 4832021-05-14
Scientifically sound laboratory controls
- 4832021-05-14
Investigations of discrepancies, failures
- 4832018-04-26
Procedures for sterile drug products
- 4832018-04-26
Strict control not exercised over labeling issued
- 4832018-04-26
Training , Education , Experience overall
- recall — Class III2018-03-28
Labeling: Label Mix-Up: Brilliant Blue G was labeled with an inaccurate auxiliary label which contained active/inactive ingredient information for incorrect product.
- warning_letter2016-11-07
FDA Warning Letter (drug product)
- recall — Class II2016-01-27
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
- recall — Class II2016-01-27
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
- recall — Class II2016-01-27
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
- recall — Class II2016-01-27
Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
Is this Pine Pharmaceuticals?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.